TL;DR: Here is what we ask during intake, logged as our BR-01 brief intake form internally:
TL;DR: We need to know whether you are targeting transepidermal water loss reduction, whether you want a 24-hour claim (which requires a specific humectant-occlusive ratio we can support with in-house SPT testing), or whether “firming” is in scope — because firming requires actives like caffeine at 3–5% or peptides, which changes your cost structure immediately
Key Technical Parameters #
Getting a body care product from concept to lab sample is where most new brand owners lose weeks — sometimes months — to avoidable back-and-forth. The core problem is not the chemistry. It is the quality of the information a brand provides at the start. This guide walks through what we actually need from you at each stage: how to structure a brief that generates useful samples on the first pass, how to evaluate what you receive, what the cost and timeline realities look like, and what happens between sample sign-off and your first production run. It is most useful for founders who have a product concept but have never engaged an OEM before — or who have, and found the process more painful than expected.
What Actually Determines Whether Your First Sample Is Usable #
Brands usually come to us with a mood board, a competitor product they like, and a vague claim — “something moisturizing, luxury feel, clean ingredients.” That gets us to a starting point. It does not get us to a sample you can approve.
The gap between a vague brief and a workable one is not creativity. It is specificity in four areas: the claim you want to make on pack, the texture the consumer is supposed to feel, the ingredient constraints you are operating under, and the market you are selling into. Every one of these changes the formulation. Leave one of them out and we are essentially guessing.
Here is what we ask during intake, logged as our BR-01 brief intake form internally:
1. What is the on-pack claim? “Deeply moisturizing” is a marketing statement. We need to know whether you are targeting transepidermal water loss reduction, whether you want a 24-hour claim (which requires a specific humectant-occlusive ratio we can support with in-house SPT testing), or whether “firming” is in scope — because firming requires actives like caffeine at 3–5% or peptides, which changes your cost structure immediately.
2. What does the texture need to do? A body lotion for a drugstore brand and a body butter for a luxury spa channel are almost different product categories in terms of rheology target. We need: application feel (light vs. rich), absorption speed (fast-dry or slow-sink), and any finish preference (matte, dewy, skin-like). If you have a benchmark product, send it to us. Physical benchmarks save at least one sample iteration.
3. What are you not allowed to put in? Ingredient exclusion lists matter more than most brands realize at brief stage. EU allergen constraints, retailer clean-beauty checklists (think Target Clean or Sephora Clean), vegan certification requirements, and fragrance restrictions all narrow the formulation space before we even start. We flag this early because some combinations of exclusions genuinely constrain performance — and we would rather tell you upfront than disappoint you at evaluation.
4. Which market are you launching in first? This is not a regulatory formality. The EU Cosmetics Regulation 1223/2009 has a restricted substances list that is meaningfully different from FDA Cosmetics Guidelines, and if you are also considering the China market, NMPA Cosmetic Regulation adds a separate registration layer that affects ingredient selection from day one. We have had brands request a formulation approved for EU and China simultaneously, then discover partway through that one of their requested botanicals is not on the NMPA positive list. That costs six weeks. Knowing the target market at brief stage prevents it.
One thing I want to be direct about: the “send me what you think is good” brief approach almost never works well. We will produce something, and it will be technically sound, but it probably will not match what you envisioned — because you had a vision we did not have access to. The briefs that generate first-pass samples worth approving are specific about at least three of the four areas above.
Sample Types, MOQ, Cost Structure, and Timeline — Side by Side #
Once a brief is accepted, the next question is always about cost and turnaround. Here is how we structure it across the main stages of development:
| Stage | What You Receive | Typical MOQ | Development Cost | Turnaround |
|---|---|---|---|---|
| Concept Sample (Pilot Batch) | 2–5 units, lab scale | No MOQ | Development fee: USD 300–800 per formula | 2–3 weeks from brief sign-off |
| Stability / Revised Sample | Updated formula + T0/T4W accelerated data | No MOQ | Included in development fee if minor revision; USD 150–300 for major reformulation | +4–6 weeks (accelerated) |
| Pre-Production Trial | Scaled batch at 50–100 kg | 200–500 units depending on format | Per-unit cost at pilot scale (20–40% above production unit cost) | 3–4 weeks after formula lock |
| First Production Batch | Full commercial batch | 1,000–3,000 units standard (format dependent) | Production unit cost + tooling if custom packaging | 6–10 weeks from PO confirmation |
The development fee question comes up constantly. Our standard structure is a fixed development fee that covers up to two rounds of revision and the initial accelerated stability run (8 weeks at 40°C / 75% RH per ICH Q1B protocol). If we are past two revisions and the formula is still not approved, we charge an incremental fee per additional iteration. This is not unusual in contract manufacturing — it reflects real lab time.
A few things worth interpreting from that table. The pre-production trial step is the one most brands want to skip. Understandable — it adds cost and time. But going directly from a 500g lab sample to a 500 kg production batch is where we see the most unpleasant surprises. Emulsion homogeneity, fragrance dispersion, and viscosity all behave differently at scale. We have had batches where a lotion formula that was perfectly stable at lab scale showed phase separation at 200 kg because of pump shear during manufacturing. The pilot trial is what catches that. For our body care product range, we flag pilot trials as non-negotiable for emulsions with fragrance loads above 1.0% or active concentrations that required specific pH adjustment during development.
Development fees are not universally applied across OEMs — some build them into unit cost, others waive them at volume thresholds. Our position is transparency: we charge the fee, we show you what it covers, and we apply it as a credit against your first production order above 3,000 units. The economics tend to work out, and it avoids the dynamic where development resources are subsidized by clients who never reach production.
Evaluating Lab Samples — What to Actually Check, and What to Ignore Until Later #
When samples arrive, we see brand owners focus on fragrance intensity and packaging aesthetics — neither of which we control at this stage because the sample is in an unbranded jar. The variables that actually matter at lab sample evaluation are texture behavior, skin compatibility, and initial stability indicators.
Texture evaluation should be systematic. Apply the product to a consistent forearm area (inside, not outside — more representative for body care consumer use), and evaluate at three time points: immediately after application, 5 minutes in, and 20 minutes in. What you are assessing: initial slip and spreadability, absorption speed, and 20-minute finish. Document this. “Feels nice” is not useful feedback. “Absorbs quickly but leaves a slightly tacky finish at 20 minutes” is feedback we can act on.
Efficacy proxies. For moisturization claims, we run corneometer testing in-house at T0 and T24 on a panel of 10 subjects. The bar we work toward internally for a 24-hour moisturization claim is a minimum 20% increase in skin hydration measured at 24 hours post-application versus untreated control — roughly consistent with what published body care clinical data reports. For context on what efficacy benchmarks look like with structured testing: a 2022 randomized controlled study (n=44, 8 weeks, twice-daily application) on a ceramide-plus-niacinamide body lotion formula showed a 34% reduction in transepidermal water loss versus vehicle, and a 27% improvement in corneometer scores versus baseline. That is the kind of endpoint we design toward when a brand wants clinical-grade claims.
Early stability signals. We send samples with a T0 appearance card — color, odor, viscosity, pH. At your end, the practical check is: store one sample at room temperature and one in a car (or a 40°C environment if you have access). Check both at 4 weeks. Color shift, phase separation, or odor change at 4 weeks under real-world conditions is a reliable early warning even without formal stability equipment. Any of those changes warrants a conversation with us before approval.
What to ignore until later: shade matching if custom colorants are involved, fragrance intensity variation across samples (there is normal lot-to-lot variation at lab scale that tightens at production), and fill weight if we are still in development packaging. These are production variables.
We are still not fully satisfied with the corneometer proxy for all body care formats — it works well for leave-on lotions and creams, less so for body oils where occlusion dynamics are different. Our current protocol for oils routes through TEWL measurement exclusively. That is an area where we would welcome better standardized methodology, but the field has not converged on one yet.
From Sample Approval to First Production Batch — The Steps Most Briefs Don’t Account For #
Sample approval feels like the finish line. It is the start of a different process.
After formula lock, there are typically six steps before product ships: formula finalization documentation, raw material procurement and incoming QC, packaging component qualification, bulk manufacturing and in-process QC, finished goods testing (microbial, stability check of production batch, pH, viscosity), and release. Per our QR-03 release checklist, no batch ships without passing all release criteria. That sounds obvious, but in practice it means timeline planning needs to account for incoming material lead times — which can run 4–8 weeks for specialty actives.
Packaging qualification is where projects slow down without warning. If you are supplying your own packaging, we need to run a compatibility check between the formula and the container. For body care — particularly products with low pH (AHA body lotions, for example) or high fragrance load — container-formula interaction is a real failure mode. We have seen fragrance migration through HDPE containers rated as “cosmetic grade” that left an off-odor in the product within six weeks. That test takes 2 weeks and should happen in parallel with production preparation, not after.
The practical timeline from sample sign-off to product in your hands, assuming packaging is confirmed and materials are in stock: 6–8 weeks. Add 4 weeks if packaging needs to be sourced, 6 weeks if there are registered actives requiring NMPA dossier updates for China. These are real numbers, not estimates. Build them into your launch plan.
A few things worth flagging as early production red flags to watch during the first batch review:
- Viscosity variance greater than 15% from approved lab sample (usually indicates mixing time or temperature deviation)
- Any visible phase separation in the bulk tank before filling — stop the batch, do not fill through it
- pH drift greater than 0.3 units from spec — this typically indicates water quality or buffer variance and affects both preservation system efficacy and active stability
- Fragrance intensity noticeably weaker than sample — check for thermal degradation during bulk manufacturing if the process involves temperatures above 70°C
One milestone recommendation: schedule a first-batch review call with your OEM production contact at the bulk manufacturing stage, before filling. Catching issues then costs a remix. Catching them after filling costs the batch.
Formulation Notes for Brand Partners #
When you brief us on a body care project, the first questions are: what market, what retail channel, and what texture are you targeting? Those three inputs alone change the formulation space materially — a mass-market body lotion for the US drugstore channel has different preservation requirements, cost targets, and texture benchmarks than a clean-beauty body butter for EU specialty retail.
The brief mistake we see most often is brands treating the benchmark product as the target rather than the starting point. We get samples from competitors and instructions to “match this.” That is a useful anchor for texture and sensory profile — but it tells us nothing about your claims, your ingredient constraints, or what you want to improve on. The brief should tell us what the benchmark gets right and what problem you are solving differently. That distinction speeds up iteration substantially.
On timeline: lab samples take 2–3 weeks from brief sign-off. Accelerated stability runs 4–8 weeks (we initiate 24-month real-time stability concurrently, per ICH Stability Guidelines). Pre-production trials add 3–4 weeks after formula lock. First production, 6–10 weeks from PO confirmation assuming materials and packaging are confirmed. Total from first brief call to finished goods: realistically 20–28 weeks for a new formula. Plan accordingly.
Frequently Asked Questions #
Do we need to pay a development fee even for simple formulas?
A: For straightforward extensions of existing base formulas — different fragrance, different texture variant — we often waive it or charge a nominal fee around USD 150. A genuinely new formula targeting a specific active claim or novel texture profile is a different scope, and the development fee reflects that. We walk through scope in the initial brief call and confirm the cost structure before any work starts.
What happens if we are in the EU and want to add a botanical extract — do we need to check the restricted list before briefing?
A: Worth doing ahead of time, yes. The EU Cosmetics Regulation 1223/2009 Annexes II and III cover prohibited and restricted substances, and some botanical extracts — particularly those with known sensitization profiles — have SCCS opinions that limit their use in leave-on body care formats. We check this as part of brief review, but if you have already shortlisted ingredients, running them against the SCCS Scientific Opinion database first saves a cycle.
We approved a sample six months ago and now want to move to production — is the formula still valid?
A: It depends on how the sample was stored and what the formula contains. If the approved sample included unstable actives (retinol, ascorbic acid, certain peptides), we recommend a fresh stability check before production. Six months at ambient or uncontrolled storage is enough to invalidate the baseline we set at approval. We flag this during the production onboarding call, but it catches brands off guard when it adds 4 weeks to their timeline.
What is the minimum order quantity for a first production run?
A: For most body care formats — lotions, creams, body butters — the floor is 1,000 units. Some formats with simpler manufacturing (body oils, salts, scrubs) can go down to 500 units. Custom tube or airless packaging typically carries a higher MOQ floor because of component minimums. We confirm this during packaging specification review, not at brief stage, since it depends on what you select.
Should we brief multiple OEMs simultaneously to compare samples?
A: Common approach, and not unreasonable. The practical issue is that sample quality varies based on how much context the OEM has — a thin brief submitted to five factories simultaneously will generate five mediocre samples. A detailed brief submitted to two carefully selected partners usually generates more useful evaluation data. We have seen brands run parallel briefs, pick one partner based on sample quality, and only then discover that the selected partner cannot support their volume requirements or target market registration. Sequencing the selection criteria matters: qualify on capability first, then evaluate samples.
Have a product concept in mind? Contact our formulation team to request a complimentary brief review.
Caffeine at 3–5% sounds clean on paper, but we’ve had real headaches with oxidative discoloration in emulsions above 4% when the water phase pH drifted past 6.8 during manufacturing — caught it at T4W accelerated and had to reformulate twice. Source matters too; the micronized grade from our German supplier disperses without the grittiness we saw with a Southeast Asian alternative we trialed in Q3 last year.
The “market you’re selling into” line in the brief criteria is doing a lot of heavy lifting that newer brands tend to underestimate. Japan’s quasi-drug classification means a firming claim with caffeine at those concentrations triggers a whole separate regulatory path before you’re anywhere near production samples, whereas in SEA we’ve generally had more flexibility on claims but run into halal certification requirements that affect which occlusive ingredients are even on the table. The BR-01 intake form probably needs a dedicated market field, not just a checkbox.
Challenge testing timing caught us off guard early on — we’d assumed a finished formula at pilot scale would behave the same microbiologically after the 50 kg scale-up, but the increased shear during manufacturing changed the emulsion structure enough that our preservative system (phenoxyethanol/ethylhexylglycerin at 0.9%/0.1%) failed ISO 11930 Category 2 on the scaled batch even though the pilot had passed clean.
Worth flagging for anyone planning EU launch: body products with a 24-hour moisturization claim technically fall under Regulation (EC) No 1223/2009 Article 20, which means your SPT or corneometry data needs to sit in the Product Information File before you can use the claim — not just be “available on request.” We got pushback from a German retailer in 2023 who wanted PIF access during onboarding, and scrambling to compile that post-formula-lock added about six weeks we hadn’t budgeted.
The “firming” example in the brief criteria is a good illustration of something brands consistently underprice — not the active cost, but the substantiation cost downstream. A peptide-based firming claim on a body lotion will typically need a minimum 4-week clinical with at least 30 subjects to hold up to scrutiny, and that’s before you factor in whether your target retailer wants their own audit trail on top of the supplier data.
The BR-01 intake form is solid in theory, but we learned the hard way that “ingredient constraints” needs to include your retailer’s restricted substances list, not just your own. We’d submitted brief sign-off to our OEM in Guangzhou without flagging that our primary retail partner ran against Credo’s Dirty List, and they formulated with a synthetic musk (Galaxolide at 0.3%) that cleared IFRA but was on the retailer’s ban list. Caught it at pre-production trial stage — 50 kg batch, already mixed — and ended up eating the reformulation cost plus a 6-week delay.
The 20–40% pilot scale premium on pre-production unit cost is real and it catches people badly when they’re trying to lock a retail price early — we ran a 75 kg trial batch on a body butter last year and the per-unit came out at $4.10 versus the $2.80 we’d modeled for production, which meant we had to go back and reformulate two of the richer emollients down to hit margin.